[ad_1]
Results from preliminary tests of the vaccine showed that it can produce antibodies without side effects, which is an indicator of resistance. However, to gain brand approval, the third stage test results must be submitted for review.
CNBG is one of the first to start working on vaccine preparation. First they began the third stage of testing in the world. In the third phase, they tested 50,000 volunteers. Two weeks ago, Sinofarm reported that its third stage test was progressing rapidly and that all related information had exceeded expectations.
Liu Jingjen, president of Sinofarm, praised the safety of the vaccine, saying there were no side effects other than the mild side effects of the vaccine. It was applied to 56,000 people before the test started abroad. None of them did. The vaccine was administered to 61 CNBG workers abroad. None of them did. But of the 16 people who did not receive, 10 were infected with corona.
The Covid-19 vaccine will be manufactured at two CNBG factories this year. Liu said that this year it will produce 100 million doses of vaccine and increase production capacity. Sinofarm’s chairman said that capacity to manufacture Rs 100 million dose vaccines will be created next year.
